Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06704269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Name: Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis — clinical trial record (NCT06704269)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorNovartis Pharmaceuticals

Started2025-04-22

View on ClinicalTrials.gov ↗

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.

Amendment history 1 change detected by DataLookout

2026-09-05

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT06704269
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Generalized Myasthenia Gravis
Enrollment	15 participants
Start Date	2025-04-22
Primary Completion	2029-10-26 (estimated)
Study Completion	2029-10-26 (estimated)
Updated on ClinicalTrials.gov	2026-09-04